Citizen Portal
Sign In

Get Full Government Meeting Transcripts, Videos, & Alerts Forever!

Get email alerts on the Health Cgm Coverage topic

No spam. Unsubscribe anytime.

Committee keeps continuous glucose monitor coverage bill under study after lengthy testimony from family members and insurers

5783663 · September 11, 2025
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.

Summary

Members asked the insurance department for a financial impact study on how a CGM coverage mandate would affect individual and small‑group premiums and deductibles; sponsors and family members urged broader access for Type 1 patients.

The Commerce and Consumer Affairs committee retained a bill on continuous glucose monitors (CGMs) for interim study after extended testimony from sponsors, medical‑policy commenters and family members of people with Type 1 diabetes.

Representative Spear, the sponsor present for the item, described the goal as reducing access barriers to CGMs because continuous monitoring can prevent progression to insulin therapy in some patients and improve glucose control, especially for juvenile onset patients. The sponsor and a parent who testified said CGMs can detect dangerous low‑glucose episodes and improve long‑term outcomes for children diagnosed young.

Representative Miles and other members raised concerns about near‑term premium and deductible impacts. Miles argued mandating coverage for CGMs across the board would likely increase premiums in the short term and that existing medical‑necessity criteria and over‑the‑counter options provide alternatives for some patients. Members asked the insurance department to model the policy’s effect on the individual and small‑group markets and to report on whether deductible or copay waivers for juvenile Type 1 patients are feasible.

A parent who identified herself as the mother of a Type 1 child described paying an annual deductible of about $6,000 and said waiving certain costsharing for juvenile patients would materially reduce hardship. Committee staff noted earlier state action reduced insulin cost sharing but said CGM coverage raises distinct actuarial issues because of metal‑level design and the way employers choose plans for small groups.

The committee asked the Insurance Department to prepare a fiscal and market impact study covering the individual and small‑group markets and to return with proposed amendment language. Committee members signaled interim study while receiving that analysis.

The discussion recorded no final vote on coverage mandates; the committee directed staff and the Insurance Department to perform the analysis before further action.